Table 1.

Patient demographics and baseline characteristics (ITT population)

CategoryPatients (N = 59)
Mean age at study entry, y (min, max)51.6 (22, 74)
Sex, n (%)
 Male37 (63)
 Female22 (37)
Race/ethnicity, n (%)
 White55 (93)
 African American1 (2)
 Other3 (5)
NYHA classification, n (%)
 150 (85)
 27 (12)
 3 or 40
 Unknown2 (3)
ECOG performance status, n (%)
 032 (54)
 125 (42)
 22 (3)
Patients with positive RET mutation status, n (%)16/24a (67)
Number of previous anticancer therapy regimens, n (%)
 025 (42)
 122 (37)
 25 (9)
 ≥37 (12)
Patients with previous conventional chemotherapy, n (%)9 (15)
Patients with previous radiotherapy, n (%)29 (49)
Patients with previous anti-VEGF therapy, n (%)26 (44)
 Cabozantinib11 (19)
 Sorafenib6 (10)
 Vandetanib4 (7)
 Motesanib3 (5)
 Sunitinib3 (5)
 Other3 (5)
Sites of metastasis at baselineb
 Liver38 (64)
 Bone19 (32)
 Lung9 (15)
Symptoms at baseline
 Diarrhea31 (53)
 Musculoskeletal pain26 (44)
  • a24 Patients were evaluated for RET mutation status.

  • bOn the basis of study entry screening.